World Health Organization Sounds Alert Over Critical Lack of Obesity Injections
Under 10% of people who could benefit from GLP-1 drugs such as Wegovy have access to them, caution the WHO as it issues its inaugural recommendations on the therapies.
Given over a billion individuals worldwide currently classified as obese, it is advocating for increased and just access to these injectable treatments.
Per estimates, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our latest guidance affirms that obesity is a chronic disease that can be treated with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are major obstacles to broad access to the jabs that can assist patients in reducing substantial body mass, says the agency.
GLP-1 Therapy Supply Crisis
Despite the present best projected case, the production of these medications could only cover about 100 million people – less than 10% of the global need, according to the health organization.
The recommendation calls on governments and firms to expand availability, by measures like licensing agreements.
A patent on a key compound – the core component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026.
How Weight-Loss Jabs Function
The injections imitate a biological compound to delay gastric emptying, reduce hunger and increase the sense of being full so individuals eat less.
Patients commonly begin shedding pounds after several weeks of beginning the regular doses.
Evidence indicates patients may regain a significant portion a year later of discontinuing the drug, when their normal food cravings return.
To be above a healthy weight elevates your likelihood for contracting medical conditions, like type 2 diabetes, heart disease, stroke, and certain malignancies.
Excess weight impacts individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
